# Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

> **NCT03590054** · PHASE1 · COMPLETED · sponsor: **Rahul Aggarwal** · enrollment: 35 (actual)

## Conditions studied

- Stage III Cutaneous Melanoma
- Stage IV Cutaneous Melanoma
- Locally Advanced Melanoma
- Locally Advanced Solid Neoplasm
- Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Metastatic Urothelial Carcinoma
- Non-Small Cell Lung Carcinoma
- Stage IB Lung Cancer AJCC v7
- Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage III Ureter Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Ureter Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DRUG:** Abexinostat
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03590054
- **Lead sponsor:** Rahul Aggarwal
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-20
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03590054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03590054, "Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03590054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*